Pancreascancer I en randomiseret fase III undersøgelse af 126 patienter med fremskreden eller metastatisk pancreascancer viste gemcitabin en statistisk signifikant højere responsrate end 5- fluorouracil udtrykt ved klinisk forbedring (henholdsvis 23, 8% og 4, 8%; p=0, 0022).
Pancreatic cancer In a randomised phase III study of 126 patients with advanced or metastatic pancreatic cancer, gemcitabine showed a statistically significant higher clinical benefit response rate than 5-fluorouracil (23.8% and 4.8% respectively, p=0.0022).